Get the Stockscreener App
1.66
2.35%
-0.04
After Hours:
1.62
-0.04
-2.41%
Annovis Bio Inc stock is traded at $1.66, with a volume of 1.44M.
It is down -2.35% in the last 24 hours and down -33.06% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$1.70
Open:
$1.74
24h Volume:
1.44M
Relative Volume:
2.89
Market Cap:
$32.35M
Revenue:
-
Net Income/Loss:
$-30.26M
P/E Ratio:
-0.8137
EPS:
-2.04
Net Cash Flow:
$-24.69M
1W Performance:
-26.55%
1M Performance:
-33.06%
6M Performance:
+27.69%
1Y Performance:
-79.07%
1-Day Range:
$1.57
$1.76
1-Week Range:
$1.57
$2.60
52-Week Range:
$1.11
$10.54
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.66 | 33.13M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Heatmap analysis for Annovis Bio Inc. and competitorsTrade Risk Summary & Expert Curated Trade Setup Alerts - newser.com
Annovis Announces $6 Million Registered Direct Offering of Common Stock - MarketScreener
How Annovis Bio Inc. stock trades during market volatilityTake Profit & Fast Exit/Entry Strategy Plans - newser.com
Why Annovis Bio Inc. stock could be next big winnerMarket Risk Summary & Reliable Intraday Trade Alerts - newser.com
Multi asset correlation models including Annovis Bio Inc.Market Rally & High Accuracy Trade Signal Alerts - newser.com
Full technical analysis of Annovis Bio Inc. stockJuly 2025 Opening Moves & Community Consensus Stock Picks - newser.com
What data driven models say about Annovis Bio Inc.’s future2025 Key Lessons & Step-by-Step Trade Execution Guides - newser.com
Is Annovis Bio Inc. stock dividend yield sustainableInsider Buying & Short-Term Trading Alerts - newser.com
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MyChesCo
Can Annovis Bio Inc. stock hit record highs againJuly 2025 Earnings & High Win Rate Trade Alerts - newser.com
Visual trend scoring systems applied to Annovis Bio Inc.Market Growth Review & Step-by-Step Trade Execution Guides - newser.com
Annovis Bio raises $6 million in registered direct offering By Investing.com - Investing.com South Africa
Annovis Bio raises $6 million in registered direct offering - Investing.com India
Annovis Bio to Raise $6 Million in Registered Direct Offering; Shares Fall - MarketScreener
Annovis announces $6 million registered direct offering of common stock - MarketScreener
Annovis Announces $6 Million Registered Direct Offering Of Common Stock - TradingView
Annovis Bio, Inc. Announces $6 Million Registered Direct Offering of Common Stock - Quiver Quantitative
Statistical indicators supporting Annovis Bio Inc.’s strengthJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
Is Annovis Bio Inc. stock in buy zone after pullback2025 Market Outlook & Smart Money Movement Tracker - newser.com
Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap - MSN
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer’s Patients - citybuzz
Will Annovis Bio’s Therapeutic Innovation Drive Stock Growth? - timothysykes.com
Annovis Bio reports buntanetap reduces inflammation in Alzheimer’s patients By Investing.com - Investing.com Australia
Annovis Bio reports buntanetap reduces inflammation in Alzheimer’s patients - Investing.com
Does Annovis Bio Inc. show high probability of reboundQuarterly Risk Review & Technical Entry and Exit Tips - newser.com
Annovis Bio Reports Promising Biomarker Results for Buntanetap in Alzheimer’s Disease Treatment - Quiver Quantitative
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment - The Manila Times
Annovis announces novel biomarker data in Alzheimer's patients supporting buntanetap's potential as a disease-modifying treatment - MarketScreener
Annovis Announces Novel Biomarker Data in Alzheimer’s - GlobeNewswire
Reduced IL-5, IL-6, S100A12, IFN-γ and NFL — Annovis' buntanetap shows biomarker signals in 2/3 AD - Stock Titan
Will Annovis Bio Inc. stock go up soon2025 Fundamental Recap & Daily Volume Surge Trade Alerts - newser.com
What analysts say about Annovis Bio Inc stockGap Up/Gap Down Analysis & Ride the Trends That Billionaires Follow - earlytimes.in
How high can Annovis Bio Inc. stock goQuarterly Portfolio Review & Safe Swing Trade Setups - newser.com
Why Annovis Bio Inc. stock stays on buy listsJuly 2025 Action & Weekly Watchlist for Hot Stocks - newser.com
Why analysts raise outlook for Annovis Bio Inc. stockQuarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
Why Annovis Bio Inc. stock is considered a top pickEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com
Ipca Laboratories Limited Earnings Review What Investors Need to KnowRetail Investor Activity & Small Investment Wealth Growth - earlytimes.in
Annovis Bio Inc Stock Analysis and ForecastVolatility Adjusted Trading & Free Fast Track Wealth Growth - earlytimes.in
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):